Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANORAMIX: NALIRIFOX Optimization and Antibiotics in Pancreatic Cancer
NCT07028424Phase 2Not yet recruiting
- Sponsor
- GERCOR
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by GERCOR. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07028424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028424.